{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-005309","form_type":"8-K","ticker":"IMCR","cik":"0001671927","company_name":"Immunocore Holdings plc","filed_at":"2024-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.055179+00:00","generated_at":"2026-06-06T09:57:33.925925+00:00","sec_items":["1.01","2.03","3.02","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Immunocore completes $402.5M convertible notes offering at 2.50% due 2030","bullets":["Aggregate principal $402.5M including $52.5M option exercise; net proceeds ~$389.3M.","2.50% interest, maturity Feb 1, 2030; initial conversion price ~$94.70/ADS (40% premium to $67.64).","Proceeds to accelerate clinical pipeline, commercial expansion, repay Pharmakon loans, and general corporate.","Offering upsized from $300M; sold in private placement to QIBs under Rule 144A.","Notes redeemable after Feb 5, 2027 if ADS price >=130% of conversion price for 20 of 30 trading days."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-005309","json":"https://secwatch.observer/filing/0001140361-24-005309.json","markdown":"https://secwatch.observer/filing/0001140361-24-005309.md","text":"https://secwatch.observer/filing/0001140361-24-005309.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671927/000114036124005309/0001140361-24-005309-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671927/000114036124005309/ef20020523_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T09:57:33.925925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0fbedb99a0b04db331b55207210773f51ab94018","claim":"Immunocore Holdings plc incurred convertible notes of $402.5 million aggregate principal amount with U.S. Bank Trust Company, National Association at 2.50% per year maturing February 1, 2030.","evidence_excerpt":"On February 2, 2024, Immunocore Holdings plc (the “Company”) completed its previously announced private offering (the “Offering”) of $402.5 million aggregate principal amount of 2.50% Convertible Senior Notes due 2030 (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $52.5 million principal amount of Notes.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671927/000114036124005309/0001140361-24-005309-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$402.5 million aggregate principal amount"},{"label":"Counterparty","value":"U.S. Bank Trust Company, National Association"},{"label":"Rate","value":"2.50% per year"},{"label":"Maturity","value":"February 1, 2030"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"f24a1264576e6046af47fd611f53f17edf728bed","claim":"Immunocore Holdings plc entered into Indenture with U.S. Bank Trust Company, National Association valued at $402.5 million aggregate principal amount (effective 2024-02-02).","evidence_excerpt":"The Notes were issued pursuant to an indenture, dated February 2, 2024 (the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671927/000114036124005309/0001140361-24-005309-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"U.S. Bank Trust Company, National Association"},{"label":"Value","value":"$402.5 million aggregate principal amount"},{"label":"Effective","value":"2024-02-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}